Insulin lispro
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| MedlinePlus | a697021 |
| Pregnancy category |
|
| Legal status | |
| Routes of administration | Subcutaneous |
| Identifiers | |
| CAS Number |
133107-64-9  |
| ATC code | A10AB04 |
| PubChem | CID 16132438 |
| DrugBank |
DB00046 |
| ChemSpider | none |
| UNII |
GFX7QIS1II  |
| KEGG |
D04477 |
| Chemical data | |
| Formula | C257H389N65O77S6 |
| Molar mass | 5813.63 g/mol |
| (what is this?) (verify) | |
Insulin lispro (marketed by Eli Lilly and Company as "Humalog") is a fast acting insulin analog. It was first approved for use in the United States in 1996, making it the first insulin analog to enter the market.[1]
Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.[2]
Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin (e.g. Insulin degludec) for good glycemic control.
Medical uses
Insulin lispro is an FDA approved drug used to treat people living with Type 1 diabetes or Type 2 diabetes.[3] Insulin lispro has non-FDA labeled uses for diabetic nephropathy prevention, diabetic neuropathy prevention, and cardiovascular disease prevention.[3]
Side effects
Common side effects include skin irritation at the site of injection, hypoglycemia, hypokalemia, and lipodystrophy.[3] Other serious side effects include anaphylaxis, and hypersensitivity reactions.[3]
Contraindications
Do not administer insulin lispro during episodes of hypoglycemia, or if the patient has a hypersensitivity to insulin lispro or any of its excipients.[3]
References
- ↑ "Drugs@FDA:FDA Approved Products: Humalog". U.S. Food and Drug Administration. Retrieved 16 November 2012.
- ↑ "Insulin Lispro: A Fast-Acting Insulin Analog". Retrieved 2007-06-08.
- 1 2 3 4 5 Product Information: HUMALOG(R) pen injection, insulin lispro (rDNA origin) pen injection. Eli Lilly and Company, Indianapolis, IN, 2007
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.